Ancestral SARS-CoV-2 driven antibody repertoire diversity in an unvaccinated individual correlates with expanded neutralization breadth
Abstract Understanding the quality of immune repertoire triggered during natural infection can provide vital clues that form the basis for development of humoral immune response in some individuals capable of broadly neutralizing pan SARS-CoV-2 variants. We assessed the diversity of neutralizing antibody responses developed in an unvaccinated individual infected with ancestral SARS-CoV-2 by examining the ability of the distinct B cell germline-derived monoclonal antibodies (mAbs) in neutralizing known and currently circulating Omicron variants by pseudovirus and authentic virus neutralization assays. The ability of the antibodies developed post vaccination in neutralizing Omicron variants was compared to that obtained at baseline of the same individual and to those obtained from Omicron breakthrough infected individuals by pseudovirus neutralization assay. Broadly SARS-CoV-2 neutralizing mAbs representing unique B cell lineages with non-overlapping epitope specificities isolated from a single donor varied in their ability to neutralize Omicron variants. Plasma antibodies developed post vaccination from this individual demonstrated neutralization of Omicron BA.1, BA.2 and BA.4 with increased magnitude and found to be comparable with those obtained from other vaccinated individuals who were infected with ancestral SARS-CoV-2. Development of B cell repertoire capable of producing antibodies with distinct affinity and specificities for the antigen immediately after infection capable of eliciting broadly neutralizing antibodies offers highest probability in protecting against evolving SARS-CoV-2 variants.Importance Development of robust neutralizing antibodies in SARS-CoV-2 convalescent individuals is known, however varies at population level. We isolated monoclonal antibodies from an individual infected with ancestral SARS-CoV-2 in early 2020 that not only varied in their B cell lineage origin but also varied in their capability and potency to neutralize all the known VOC and currently circulating Omicron variants. This indicated establishment of unique lineages that contributed in forming B cell repertoire in this particular individual immediately following infection giving rise to diverse antibody responses that could compensate each other in providing broadly neutralizing polyclonal antibody response. Individuals who were able to produce such potent polyclonal antibody responses after infection have a higher chance of being protected from evolving SARS-CoV-2 variants..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deshpande, Suprit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.10.19.512979 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI037645943 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI037645943 | ||
| 003 | DE-627 | ||
| 005 | 20240425104149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221022s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.10.19.512979 |2 doi | |
| 035 | |a (DE-627)XBI037645943 | ||
| 035 | |a (biorXiv)10.1101/2022.10.19.512979 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deshpande, Suprit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ancestral SARS-CoV-2 driven antibody repertoire diversity in an unvaccinated individual correlates with expanded neutralization breadth |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Understanding the quality of immune repertoire triggered during natural infection can provide vital clues that form the basis for development of humoral immune response in some individuals capable of broadly neutralizing pan SARS-CoV-2 variants. We assessed the diversity of neutralizing antibody responses developed in an unvaccinated individual infected with ancestral SARS-CoV-2 by examining the ability of the distinct B cell germline-derived monoclonal antibodies (mAbs) in neutralizing known and currently circulating Omicron variants by pseudovirus and authentic virus neutralization assays. The ability of the antibodies developed post vaccination in neutralizing Omicron variants was compared to that obtained at baseline of the same individual and to those obtained from Omicron breakthrough infected individuals by pseudovirus neutralization assay. Broadly SARS-CoV-2 neutralizing mAbs representing unique B cell lineages with non-overlapping epitope specificities isolated from a single donor varied in their ability to neutralize Omicron variants. Plasma antibodies developed post vaccination from this individual demonstrated neutralization of Omicron BA.1, BA.2 and BA.4 with increased magnitude and found to be comparable with those obtained from other vaccinated individuals who were infected with ancestral SARS-CoV-2. Development of B cell repertoire capable of producing antibodies with distinct affinity and specificities for the antigen immediately after infection capable of eliciting broadly neutralizing antibodies offers highest probability in protecting against evolving SARS-CoV-2 variants.Importance Development of robust neutralizing antibodies in SARS-CoV-2 convalescent individuals is known, however varies at population level. We isolated monoclonal antibodies from an individual infected with ancestral SARS-CoV-2 in early 2020 that not only varied in their B cell lineage origin but also varied in their capability and potency to neutralize all the known VOC and currently circulating Omicron variants. This indicated establishment of unique lineages that contributed in forming B cell repertoire in this particular individual immediately following infection giving rise to diverse antibody responses that could compensate each other in providing broadly neutralizing polyclonal antibody response. Individuals who were able to produce such potent polyclonal antibody responses after infection have a higher chance of being protected from evolving SARS-CoV-2 variants. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Ansari, Mohammed Yousuf |e verfasserin |4 aut | |
| 700 | 1 | |a Sutar, Jyoti |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Payel |e verfasserin |4 aut | |
| 700 | 1 | |a Hingankar, Nitin |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Sohini |e verfasserin |4 aut | |
| 700 | 1 | |a Jayal, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Savita |e verfasserin |4 aut | |
| 700 | 1 | |a Anantharaj, Anbalagan |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Janmejay |e verfasserin |4 aut | |
| 700 | 1 | |a Chattopadhyay, Souvick |e verfasserin |4 aut | |
| 700 | 1 | |a Raghavan, Sreevatsan |e verfasserin |4 aut | |
| 700 | 1 | |a Gosain, Mudita |e verfasserin |4 aut | |
| 700 | 1 | |a Chauhan, Supriya |e verfasserin |4 aut | |
| 700 | 1 | |a Shrivas, Shweta |e verfasserin |4 aut | |
| 700 | 1 | |a Prasad, Chaman |e verfasserin |4 aut | |
| 700 | 1 | |a Chauhan, Sangeeta |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Jana, Pradipta |e verfasserin |4 aut | |
| 700 | 1 | |a Thiruvengadam, Ramachandran |e verfasserin |4 aut | |
| 700 | 1 | |a Kshetrapal, Pallavi |e verfasserin |4 aut | |
| 700 | 1 | |a Wadhwa, Nitya |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Bhabatosh |e verfasserin |4 aut | |
| 700 | 1 | |a Batra, Gaurav |e verfasserin |4 aut | |
| 700 | 1 | |a Medigeshi, Guruprasad |e verfasserin |0 (orcid)0000-0001-5333-9743 |4 aut | |
| 700 | 1 | |a Sok, Devin |e verfasserin |0 (orcid)0000-0002-9354-1740 |4 aut | |
| 700 | 1 | |a Bhatnagar, Shinjini |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Pramod Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharya, Jayanta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1128/spectrum.04332-22 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.10.19.512979 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||